<DOC>
	<DOC>NCT00672477</DOC>
	<brief_summary>This study will evaluate the safety and efficacy of methylnaltrexone administered as subcutaneous injections in subjects who have opioid-induced constipation and an advanced illness. The hypothesis is that methylnaltrexone will be safe and effective in relieving opioid-induced constipation in these subjects.</brief_summary>
	<brief_title>Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Analgesics, Opioid</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<mesh_term>Methylnaltrexone</mesh_term>
	<criteria>Is an adult 18 years of age or older Has a diagnosis of advanced illness (ie, a terminal illness such as incurable cancer or other endstage disease) Has a life expectancy of at least 1 month. Is receiving opioids on a regular schedule (not just asneeded or rescue doses) for the control of pain or discomfort for at least 2 weeks before the first dose of study drug. Has constipation that is caused by opioid medications. Has a known or suspected allergy to methylnaltrexone or other similar compounds (e.g. naltrexone or naloxone). Has a known or suspected mechanical gastrointestinal obstruction. Has any potential nonopioid cause of bowel dysfunction that might be a major contributor to the constipation. Has any other clinically important abnormalities as determined by the investigator that may interfere with his or her participation in or compliance with the study. Receiving opioid antagonist or partial antagonist products.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>opioid-induced constipation</keyword>
</DOC>